Dulaglutide
Experience
Log in to add your own experience.
Problems
Titration strategies
→ 1.5 mg SC weekly × ≥4 weeks (most common maintenance) → 3 mg weekly × ≥4 weeks if additional HbA1c reduction needed → 4.5 mg weekly (max)[1]
The 0.75 mg starting dose is therapeutic (unlike the non-therapeutic ramps with semaglutide and tirzepatide). Most patients escalate to 1.5 mg within the first month.Effects
- Early satiety (less pronounced than with semaglutide/tirzepatide at equipotent HbA1c reduction)[citation needed]
- Nausea, usually mild-to-moderate, peaks in first 2–4 weeks[1]
- Diarrhea / constipation[1]
- Abdominal pain[1]
- Decreased appetite[1]
- Injection-site reactions, uncommon, generally mild[1]
GI tolerability is generally considered modestly better than weekly exenatide and comparable to or slightly better than weekly semaglutide at equivalent glycemic effect.[citation needed]
Pharmacokinetics
Chemistry. Fc-fusion construct: two identical GLP-1 analog peptides (each modified at positions 8, 22, 36 for DPP-4 resistance and reduced immunogenicity) linked to a human IgG4 Fc fragment via a small glycine-rich peptide linker. The Fc tail drives the long half-life through FcRn recycling.[2]
The Fc-IgG4 fusion confers protection from renal filtration (~63 kDa, well above the glomerular cutoff) and triggers FcRn-mediated recycling, producing a terminal half-life of ~120 hours.[2][1] Cleared by proteolytic catabolism; no CYP-mediated metabolism. No dose adjustment for renal or hepatic impairment.[1]
The large molecular size limits both injection-site dispersion and oral bioavailability, dulaglutide cannot be formulated for oral use.Pharmacodynamics
Receptor pharmacology. Selective long-acting agonist of the GLP-1 receptor. The Fc-IgG4 structure differentiates it pharmacokinetically (large protein cleared by FcRn-mediated recycling rather than albumin binding) but the receptor pharmacology is the standard GLP-1 RA profile.[2]
At maintenance doses:
- HbA1c reduction of ~0.8–1.5 percentage points (1.5 mg/wk) and ~1.6–1.9 (4.5 mg/wk) in T2DM[4]
- Weight loss of ~2–5 kg, dose-dependent[4]
- 12% relative risk reduction in MACE (REWIND)[3]
- Modest SBP reduction (~1–2 mmHg)[1]
Interactions
Pregnancy and lactation
Monitoring
- Baseline: HbA1c, weight, BP, renal function, lipid panel
- Personal or family history of MTC or MEN2, contraindicated, do not start[1]
- Every 3 months for first year: HbA1c, weight, GI tolerability, signs of pancreatitis or gallbladder disease
- Annual: renal function, lipids
- Pre-procedure: hold weekly dose ≥7 days before any planned anesthesia[5]
Patient counseling
- Use the pre-filled pen as directed; the needle is hidden, patients do not see it. This is often the preferred GLP-1 RA for needle-averse patients.[citation needed]
- GI side effects peak in first 2–4 weeks, then attenuate.[1]
- If a weekly dose is missed: take within 3 days; if >3 days, skip and resume on the next regular day.[1]
- Surgery: hold dose 7 days pre-op.[5]
- Pregnancy planning: stop ≥1 month before trying to conceive.[1]
Relevant anecdote
0
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
See also
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 1.23 1.24 US FDA. Trulicity (dulaglutide) prescribing information. Eli Lilly. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125469s044lbl.pdf
- ↑ 2.0 2.1 2.2 2.3 Glaesner W, Vick AM, Millican R et al. (2010). Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 26(4):287–96. doi:10.1002/dmrr.1080
- ↑ 3.0 3.1 Gerstein HC et al. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet 394(10193):121–30. doi:10.1016/S0140-6736(19)31149-3
- ↑ 4.0 4.1 Frias JP, Bonora E, Nevarez Ruiz L et al. (2021). Efficacy and safety of dulaglutide 3 and 4.5 mg versus 1.5 mg in metformin-treated patients with type 2 diabetes (AWARD-11). Diabetes Care 44(3):765–73. doi:10.2337/dc20-1473
- ↑ 5.0 5.1 Kindel TL et al. (2024). Perioperative GLP-1 receptor agonist safety guidance. Surg Obes Relat Dis 20(12):1183–8.